Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA
Gains BsUFA Goal Date Of 21 April 2024 For Biosimilar Rival To Lucentis
Xbrane has a goal date in April 2024 for its ranibizumab biosimilar • Source: Shutterstock
More from Biosimilars
More from Products